Abstract |
Single-dose treatment of vulvovaginal candidiasis with a 500 mg clotrimazole vaginal tablet was compared to 3-day treatment with two 100 mg vaginal tablets administered daily in 115 patients enrolled in a double-blind trial, 101 of whom were evaluated for efficacy. Patients with clinically and mycologically active disease were treated (visit 1) and examined at 5 to 10 days (visit 2) and again at least 27 days (visit 3) post treatment. At visit 2, mycologic tests and clinical examinations were negative in 37 of 48 patients receiving single-dose treatment (77%) and in 47 of 53 patients receiving 3-day treatment (89%). Corresponding results for visit 3 were 65% and 74%, respectively. There were no significant differences in treatment response between groups, and only three patients reported adverse reactions. These data show that single-dose treatment with clotrimazole, 500 mg, is as safe and effective as the more complex 3-day regimen.
|
Authors | T Lebherz, E Guess, N Wolfson |
Journal | American journal of obstetrics and gynecology
(Am J Obstet Gynecol)
Vol. 152
Issue 7 Pt 2
Pg. 965-8
(Aug 01 1985)
ISSN: 0002-9378 [Print] United States |
PMID | 3895962
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Imidazoles
- Tablets
- Clotrimazole
|
Topics |
- Adult
- Aged
- Candidiasis, Vulvovaginal
(drug therapy)
- Clinical Trials as Topic
- Clotrimazole
(administration & dosage, therapeutic use)
- Double-Blind Method
- Drug Administration Schedule
- Female
- Humans
- Imidazoles
(administration & dosage)
- Middle Aged
- Pregnancy
- Tablets
- Time Factors
|